Logo image of ASPN

ASPEN AEROGELS INC (ASPN) Stock Fundamental Analysis

USA - NYSE:ASPN - US04523Y1055 - Common Stock

8.13 USD
-0.37 (-4.35%)
Last: 10/27/2025, 4:02:00 PM
8.13 USD
0 (0%)
After Hours: 10/27/2025, 4:02:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ASPN. ASPN was compared to 82 industry peers in the Chemicals industry. While ASPN seems to be doing ok healthwise, there are quite some concerns on its profitability. ASPN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ASPN had positive earnings in the past year.
ASPN had a positive operating cash flow in the past year.
In the past 5 years ASPN reported 4 times negative net income.
In the past 5 years ASPN reported 4 times negative operating cash flow.
ASPN Yearly Net Income VS EBIT VS OCF VS FCFASPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M

1.2 Ratios

ASPN has a Return On Assets of -59.40%. This is amonst the worse of the industry: ASPN underperforms 93.90% of its industry peers.
Looking at the Return On Equity, with a value of -101.02%, ASPN is doing worse than 85.37% of the companies in the same industry.
With a decent Return On Invested Capital value of 6.09%, ASPN is doing good in the industry, outperforming 67.07% of the companies in the same industry.
Industry RankSector Rank
ROA -59.4%
ROE -101.02%
ROIC 6.09%
ROA(3y)-5.96%
ROA(5y)-12.11%
ROE(3y)-8.57%
ROE(5y)-17.34%
ROIC(3y)N/A
ROIC(5y)N/A
ASPN Yearly ROA, ROE, ROICASPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40

1.3 Margins

ASPN has a Operating Margin (7.73%) which is in line with its industry peers.
ASPN's Gross Margin of 36.33% is fine compared to the rest of the industry. ASPN outperforms 75.61% of its industry peers.
In the last couple of years the Gross Margin of ASPN has grown nicely.
Industry RankSector Rank
OM 7.73%
PM (TTM) N/A
GM 36.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y70.57%
GM growth 5Y16.45%
ASPN Yearly Profit, Operating, Gross MarginsASPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40

More info and screens

4

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ASPN is destroying value.
Compared to 1 year ago, ASPN has more shares outstanding
The number of shares outstanding for ASPN has been increased compared to 5 years ago.
Compared to 1 year ago, ASPN has a worse debt to assets ratio.
ASPN Yearly Shares OutstandingASPN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ASPN Yearly Total Debt VS Total AssetsASPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

ASPN has an Altman-Z score of 0.83. This is a bad value and indicates that ASPN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ASPN (0.83) is worse than 82.93% of its industry peers.
ASPN has a Debt/Equity ratio of 0.38. This is a healthy value indicating a solid balance between debt and equity.
ASPN's Debt to Equity ratio of 0.38 is fine compared to the rest of the industry. ASPN outperforms 74.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Altman-Z 0.83
ROIC/WACC0.72
WACC8.48%
ASPN Yearly LT Debt VS Equity VS FCFASPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 3.98 indicates that ASPN has no problem at all paying its short term obligations.
ASPN has a Current ratio of 3.98. This is amongst the best in the industry. ASPN outperforms 89.02% of its industry peers.
A Quick Ratio of 3.31 indicates that ASPN has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.31, ASPN belongs to the top of the industry, outperforming 93.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.98
Quick Ratio 3.31
ASPN Yearly Current Assets VS Current LiabilitesASPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1700.00% over the past year.
Looking at the last year, ASPN shows a quite strong growth in Revenue. The Revenue has grown by 11.18% in the last year.
The Revenue has been growing by 26.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.38%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y54.99%
Revenue growth 5Y26.56%
Sales Q2Q%-33.75%

3.2 Future

The Earnings Per Share is expected to grow by 41.38% on average over the next years. This is a very strong growth
ASPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.96% yearly.
EPS Next Y-846.37%
EPS Next 2Y-72.49%
EPS Next 3Y3.33%
EPS Next 5Y41.38%
Revenue Next Year-32.59%
Revenue Next 2Y-14.45%
Revenue Next 3Y0.58%
Revenue Next 5Y9.96%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ASPN Yearly Revenue VS EstimatesASPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 1B 2B 3B 4B 5B
ASPN Yearly EPS VS EstimatesASPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ASPN is valuated quite expensively with a Price/Earnings ratio of 50.81.
65.85% of the companies in the same industry are cheaper than ASPN, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 26.89. ASPN is valued rather expensively when compared to this.
The Price/Forward Earnings ratio is 206.65, which means the current valuation is very expensive for ASPN.
67.07% of the companies in the same industry are cheaper than ASPN, based on the Price/Forward Earnings ratio.
ASPN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.99.
Industry RankSector Rank
PE 50.81
Fwd PE 206.65
ASPN Price Earnings VS Forward Price EarningsASPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 50 100 150 200

4.2 Price Multiples

The rest of the industry has a similar Enterprise Value to EBITDA ratio as ASPN.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 12.83
ASPN Per share dataASPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-72.49%
EPS Next 3Y3.33%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ASPN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASPEN AEROGELS INC

NYSE:ASPN (10/27/2025, 4:02:00 PM)

After market: 8.13 0 (0%)

8.13

-0.37 (-4.35%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/amc
Inst Owners73.41%
Inst Owner Change0.11%
Ins Owners1.14%
Ins Owner Change0.26%
Market Cap669.59M
Revenue(TTM)397.18M
Net Income(TTM)-311913000
Analysts75.71
Price Target9.77 (20.17%)
Short Float %12.46%
Short Ratio5.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.34%
Min EPS beat(2)-25.4%
Max EPS beat(2)16.72%
EPS beat(4)3
Avg EPS beat(4)98.13%
Min EPS beat(4)-25.4%
Max EPS beat(4)343.94%
EPS beat(8)7
Avg EPS beat(8)115.79%
EPS beat(12)10
Avg EPS beat(12)84.36%
EPS beat(16)10
Avg EPS beat(16)54.19%
Revenue beat(2)1
Avg Revenue beat(2)-0.63%
Min Revenue beat(2)-6.73%
Max Revenue beat(2)5.47%
Revenue beat(4)2
Avg Revenue beat(4)0.96%
Min Revenue beat(4)-6.73%
Max Revenue beat(4)5.47%
Revenue beat(8)6
Avg Revenue beat(8)7.28%
Revenue beat(12)7
Avg Revenue beat(12)2.31%
Revenue beat(16)10
Avg Revenue beat(16)3.56%
PT rev (1m)0%
PT rev (3m)-22.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)60.52%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.38%
Valuation
Industry RankSector Rank
PE 50.81
Fwd PE 206.65
P/S 1.69
P/FCF N/A
P/OCF 11.51
P/B 2.17
P/tB 2.17
EV/EBITDA 12.83
EPS(TTM)0.16
EY1.97%
EPS(NY)0.04
Fwd EY0.48%
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.71
OCFY8.69%
SpS4.82
BVpS3.75
TBVpS3.75
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.67
Profitability
Industry RankSector Rank
ROA -59.4%
ROE -101.02%
ROCE 6.87%
ROIC 6.09%
ROICexc 9.74%
ROICexgc 9.74%
OM 7.73%
PM (TTM) N/A
GM 36.33%
FCFM N/A
ROA(3y)-5.96%
ROA(5y)-12.11%
ROE(3y)-8.57%
ROE(5y)-17.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y70.57%
GM growth 5Y16.45%
F-Score4
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.38
Debt/FCF N/A
Debt/EBITDA 2.2
Cap/Depr 275.05%
Cap/Sales 15.47%
Interest Coverage 2.27
Cash Conversion 109.6%
Profit Quality N/A
Current Ratio 3.98
Quick Ratio 3.31
Altman-Z 0.83
F-Score4
WACC8.48%
ROIC/WACC0.72
Cap/Depr(3y)1152.87%
Cap/Depr(5y)727.63%
Cap/Sales(3y)63.74%
Cap/Sales(5y)41.19%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1700%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-152.38%
EPS Next Y-846.37%
EPS Next 2Y-72.49%
EPS Next 3Y3.33%
EPS Next 5Y41.38%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y54.99%
Revenue growth 5Y26.56%
Sales Q2Q%-33.75%
Revenue Next Year-32.59%
Revenue Next 2Y-14.45%
Revenue Next 3Y0.58%
Revenue Next 5Y9.96%
EBIT growth 1Y158.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-34.26%
EBIT Next 3Y26.7%
EBIT Next 5Y26.71%
FCF growth 1Y99.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y161.96%
OCF growth 3YN/A
OCF growth 5YN/A

ASPEN AEROGELS INC / ASPN FAQ

Can you provide the ChartMill fundamental rating for ASPEN AEROGELS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ASPN.


What is the valuation status for ASPN stock?

ChartMill assigns a valuation rating of 0 / 10 to ASPEN AEROGELS INC (ASPN). This can be considered as Overvalued.


How profitable is ASPEN AEROGELS INC (ASPN) stock?

ASPEN AEROGELS INC (ASPN) has a profitability rating of 2 / 10.


Can you provide the PE and PB ratios for ASPN stock?

The Price/Earnings (PE) ratio for ASPEN AEROGELS INC (ASPN) is 50.81 and the Price/Book (PB) ratio is 2.17.


What is the earnings growth outlook for ASPEN AEROGELS INC?

The Earnings per Share (EPS) of ASPEN AEROGELS INC (ASPN) is expected to decline by -846.37% in the next year.